SCHEMBL30533745

SCHEMBL30533745

CC(C)(C)OC(=O)N1CCc2cccc(OCCN)c2[C@H]1CN1C(=O)c2ccccc2C1=O

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 14/20 0.44
NFE2L2 Q16236 4/20 0.44
ALDH1A1 P00352 2/20 0.42
NPSR1 Q6W5P4 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
MAPK1 P28482 1/20 0.41
ATM Q13315 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MAPT P10636 2/20 0.38
LMNA P02545 1/20 0.38
RECQL P46063 1/20 0.38
MEN1 O00255 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
KMT2A Q03164 1/20 0.38
HSD11B1 P28845 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30256353 0.90 KEAP1 (0.44) KEAP1NFE2L2ALDH1A1NPSR1SMN1; SMN2
SCHEMBL25264776 0.90 KEAP1 (0.44) KEAP1NFE2L2ALDH1A1NPSR1SMN1; SMN2
SCHEMBL25187459 0.90 KEAP1 (0.44) KEAP1NFE2L2ALDH1A1NPSR1SMN1; SMN2
SCHEMBL28594808 0.88 KEAP1 (0.48) KEAP1NFE2L2ALDH1A1NPSR1SMN1; SMN2
SCHEMBL30256146 0.87 KEAP1 (0.41) KEAP1NFE2L2ALDH1A1NPSR1SMN1; SMN2
SCHEMBL23959356 0.87 KEAP1 (0.41) KEAP1NFE2L2ALDH1A1NPSR1SMN1; SMN2
SCHEMBL25555241 0.87 KEAP1 (0.41) KEAP1NFE2L2ALDH1A1NPSR1SMN1; SMN2
SCHEMBL24174323 0.86 KEAP1 (0.41) KEAP1NFE2L2ALDH1A1NPSR1SMN1; SMN2
SCHEMBL30533717 0.86 KEAP1 (0.41) KEAP1NFE2L2ALDH1A1NPSR1SMN1; SMN2
SCHEMBL26375843 0.86 KEAP1 (0.41) KEAP1NFE2L2ALDH1A1NPSR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4252755-B1 THERAPEUTIC COMPOUNDS C4X DISCOVERY LTD (GB) 2025-05-14 EP disclosed
US-20250084075-A1 THERAPEUTIC COMPOUNDS C4X DISCOVERY LIMITED (GB) 2025-03-13 US disclosed
CN-119569706-A Therapeutic compounds 希四克斯探索有限公司 2025-03-07 CN disclosed
CN-112996785-B Therapeutic compounds 希四克斯探索有限公司 2024-12-06 CN disclosed
US-12098148-B2 Therapeutic compounds C4X DISCOVERY LIMITED (GB) 2024-09-24 US disclosed
EP-4252755-A2 THERAPEUTIC COMPOUNDS C4x Discovery Limited (GB) 2023-10-04 EP disclosed
EP-3870578-B1 THERAPEUTIC COMPOUNDS C4X DISCOVERY LTD (GB) 2023-08-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12098148-B2 Therapeutic compounds NFE2L2, KEAP1, NQO1 KEAP1 2/4885NFE2L2 1/4885ALDH1A1 307/4885
US-20250084075-A1 THERAPEUTIC COMPOUNDS NFE2L2, KEAP1, NQO1 KEAP1 2/4885NFE2L2 1/4885ALDH1A1 307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.